California-based 4D Molecular Therapeutics is downsizing by 25% its current and planned roles in an effort to better realign its resources, the company announced on Wednesday. The layoffs will primarily affect staff supporting early-stage R&D activities and will allow the company to “drive late-stage execution,” as per the announcement.
